172 related articles for article (PubMed ID: 36795892)
1. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy.
Cole AJ; Panesso-Gómez S; Shah JS; Ebai T; Jiang Q; Gumusoglu-Acar E; Bello MG; Vlad A; Modugno F; Edwards RP; Buckanovich RJ
Clin Cancer Res; 2023 May; 29(10):1969-1983. PubMed ID: 36795892
[TBL] [Abstract][Full Text] [Related]
2. NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer.
Cole AJ; Iyengar M; Panesso-Gómez S; O'Hayer P; Chan D; Delgoffe GM; Aird KM; Yoon E; Bai S; Buckanovich RJ
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32182216
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
Karve TM; Preet A; Sneed R; Salamanca C; Li X; Xu J; Kumar D; Rosen EM; Saha T
PLoS One; 2012; 7(6):e37697. PubMed ID: 22685544
[TBL] [Abstract][Full Text] [Related]
4. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.
Seachrist DD; Sizemore ST; Johnson E; Abdul-Karim FW; Weber Bonk KL; Keri RA
Breast Cancer Res; 2017 Jun; 19(1):66. PubMed ID: 28583174
[TBL] [Abstract][Full Text] [Related]
5. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
6. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
7. FOXL2 and BMP2 act cooperatively to regulate follistatin gene expression during ovarian development.
Kashimada K; Pelosi E; Chen H; Schlessinger D; Wilhelm D; Koopman P
Endocrinology; 2011 Jan; 152(1):272-80. PubMed ID: 21084449
[TBL] [Abstract][Full Text] [Related]
8. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
9. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
10. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
11. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia.
Korzun T; Moses AS; Kim J; Patel S; Schumann C; Levasseur PR; Diba P; Olson B; Rebola KGO; Norgard M; Park Y; Demessie AA; Eygeris Y; Grigoriev V; Sundaram S; Pejovic T; Brody JR; Taratula OR; Zhu X; Sahay G; Marks DL; Taratula O
Small; 2022 Nov; 18(44):e2204436. PubMed ID: 36098251
[TBL] [Abstract][Full Text] [Related]
13. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
14. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
15. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
16. Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.
Hooks SB; Callihan P; Altman MK; Hurst JH; Ali MW; Murph MM
Mol Cancer; 2010 Nov; 9():289. PubMed ID: 21044322
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
Song J; Yang P; Lu J
Cancer Biomark; 2020; 27(1):51-61. PubMed ID: 31683459
[TBL] [Abstract][Full Text] [Related]
18. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
19. A pre-existing population of ZEB2
Francescangeli F; Contavalli P; De Angelis ML; Careccia S; Signore M; Haas TL; Salaris F; Baiocchi M; Boe A; Giuliani A; Tcheremenskaia O; Pagliuca A; Guardiola O; Minchiotti G; Colace L; Ciardi A; D'Andrea V; La Torre F; Medema J; De Maria R; Zeuner A
J Exp Clin Cancer Res; 2020 Jan; 39(1):2. PubMed ID: 31910865
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
